Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Germany's COVID-19 cases hit new record as labs warn of testing crunch

Published 01/13/2022, 08:38 AM
Updated 01/13/2022, 08:40 AM
© Reuters. FILE PHOTO: A label on a plastic vial containing a test for the coronavirus marks a priority test at the Wisplinghoff medical laboratory amid the coronavirus disease (COVID-19) pandemic in Cologne, Germany, December 20, 2021. REUTERS/Thilo Schmuelgen
LH
-

BERLIN (Reuters) - Germany on Thursday reported a record of more than 81,000 COVID-19 infections in a day as the government's coronavirus crisis manager warned of possible bottlenecks in testing.

The previous daily record was on Wednesday with 80,430 new cases. Thursday's death toll also rose by 316 to reach 115,051.

The head of Germany's federal coronavirus crisis team Carsten Breuer said workers in critical infrastructure sectors will be prioritised if COVID-19 testing capacity tightens.

"As with all scarce resources, we will certainly have to pool capacities where necessary. This also applies to tests," Breuer told Sueddeutsche Zeitung.

Health Minister Karl Lauterbach on Thursday said Germany had the means to handle the current coronavirus situation.

Germany's labs association ALM on Tuesday said PCR testing rose by 56% in the first week of 2022 compared with the previous week.

Health authorities and laboratories in the north-western state of Bremen, which has the highest infection incidence in Germany, said the shortages were not in available PCR tests but in staff and testing capacity.

"That means there are delays until a PCR test is evaluated," said Lukas Fuhrmann, spokesperson for Bremen's health senate, adding that tests could now take up to 72 hours until they are evaluated.

© Reuters. FILE PHOTO: A label on a plastic vial containing a test for the coronavirus marks a priority test at the Wisplinghoff medical laboratory amid the coronavirus disease (COVID-19) pandemic in Cologne, Germany, December 20, 2021. REUTERS/Thilo Schmuelgen

Andreas Gerritzen, the director of MVZ Medical Laboratory (NYSE:LH) in Bremen said demand on testing was twice as high as the laboratory could handle. Giving up on variant testing could ease the burden on labs, he said.

"Each variant testing is as complex as 2 normal PCR tests," Gerritzen said, adding that the laboratory has shifted its capacity to cover the high demand. "There is no weekend and there is no night without activity. We are trying to cope with the corresponding figures with this special mission."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.